The American Medical Association (AMA) has advocated for insurance companies and federal payers to fully cover new obesity treatments, such as Wegovy and Ozempic, despite their high costs. The AMA recognises obesity as a significant health concern and has passed a resolution supporting health insurance coverage for FDA-approved obesity treatments. Medicare currently doesn’t cover weight-loss drugs, and private insurers often view such treatments as non-essential, but change may be on the horizon.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
